Use of Direct-acting Antiviral Therapy to Prevent Spread of HCV Infection for Patients Receiving a HCV Positive Kidney Transplant as a HCV Negative Recipient
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 31 Dec 2018
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 18 Dec 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 30 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Oct 2018.
- 28 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Jun 2018.